Detalhe da pesquisa
1.
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
N Engl J Med
; 386(23): 2178-2187, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35569036
2.
Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Eur Respir J
; 61(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041751
3.
Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.
Respirology
; 28(12): 1147-1153, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646126
4.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
N Engl J Med
; 380(26): 2518-2528, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31112379
5.
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
N Engl J Med
; 381(18): 1718-1727, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566307
6.
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
Eur Respir J
; 59(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34475231
7.
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
Respirology
; 27(4): 294-300, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35224814
8.
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
N Engl J Med
; 379(18): 1722-1731, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30220235
9.
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.
Eur Respir J
; 58(1)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33419890
10.
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Respir Res
; 22(1): 84, 2021 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33726766
11.
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. Reply.
N Engl J Med
; 387(8): 762, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001725
12.
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
Respir Res
; 21(1): 7, 2020 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31906942
13.
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Respir Res
; 21(1): 36, 2020 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32000772
14.
Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
Respirology
; 25(4): 410-416, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31329360
15.
Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
Am J Respir Crit Care Med
; 200(12): 1505-1512, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31365829
16.
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
BMC Pulm Med
; 20(1): 3, 2020 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914963
17.
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
Eur Respir J
; 53(1)2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442716
18.
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Eur Respir J
; 54(3)2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285305
19.
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Am J Respir Crit Care Med
; 197(3): 356-363, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28889759
20.
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.
Thorax
; 73(6): 581-583, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993537